Theresia Santi

Dr. Theresia Santi

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
Theresia SantiTheresia Santi
Theresia Santi
VSVeli Sungono
Veli Sungono
LKLina Kamarga
Lina Kamarga
BSBaringin De Samakto
Baringin De Samakto
FHFerry Hidayat
Ferry Hidayat
JJJuandy Jo
Juandy Jo
Purpose: This study was performed to investigate humoral immune response and adverse events upon the heterologous prime-boost with a single dose of the mRNA-1273 vaccine among fully CoronaVac-vaccinated, infection-naive healthcare workers in Indonesia. Materials and Methods: One hundred twenty-five eligible healthcare workers were recruited from one hospital for this prospective cohort study. Blood collection was conducted twice, i.e., on 7 days before and 28 days after the booster vaccination. The titer of anti-SARS-CoV-2 receptor-binding domain (RBD) antibodies was quantified accordingly. The post-vaccination adverse event was recorded for both CoronaVac and mRNA-1273 vaccinations. Any breakthrough infection was monitored during the follow-up period. Wilcoxon matched-pairs signed rank test was used to test differences between groups. Results: A significant increase was observed in the titer of anti-SARS-CoV-2 RBD antibodies upon receiving the mRNA-1273 booster (geometric mean titers of 65.57 and 47,445 U/mL in pre and post-booster, respectively), supporting the argument to use heterologous prime-boost vaccination to improve the protection against COVID-19 in a high-risk population. The mRNA-1273 vaccine, however, caused a higher frequency of adverse events than the CoronaVac vaccine. Nonetheless, the adverse events were considered minor medical events and temporary as all subjects were not hospitalized and fully recovered. Of note, no breakthrough infection was observed during the follow-up to 12 weeks post-booster. Conclusion: The heterologous prime-boost vaccination of healthcare workers with a single dose of the mRNA-1273 vaccine generated a significant elevation in humoral immune response towards RBD of SARS-CoV-2 and was associated with a higher frequency, but minor and transient, adverse events.

1 January 2023 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
Theresia SantiTheresia Santi
Theresia Santi
BHBadriul Hegar
Badriul Hegar
ZMZakiudin Munasir
Zakiudin Munasir
APAri Prayitno
Ari Prayitno
RWRetno Asti Werdhani
Retno Asti Werdhani
Yvan VandenplasYvan Vandenplas
Yvan Vandenplas
Santi T, et al. Clin Exp Vaccine Res. 2023 Jul;12(3):240-248. https://doi.org/10.7774/cevr.2023.12.3.240

1 December 2022 in Infection & Chemotherapy
Verified
Journal Article
Open access
Theresia SantiTheresia Santi
Theresia Santi
LKLina Kamarga
Lina Kamarga
BSBaringin De Samakto
Baringin De Samakto
JJJuandy Jo
Juandy Jo
It remains unknown whether the Indonesian healthcare workers (HCWs) who had received two doses of CoronaVac vaccine and one dose of mRNA-1273 booster could be protected during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron wave. In total, 125 infection-naive and 10 previously infected HCWs were recruited. The mRNA-1273 booster substantially increased titer of anti-SARS-CoV-2 spike protein receptor-binding domain antibodies. However, the monitoring revealed that 34 out of 125 infection-naive (27.2%) and 3 out of 10 previously infected HCWs (30.0%) were infected during the Omicron wave. All infected HCWs were either asymptomatic or having mild coronavirus disease 2019 (COVID-19) and subsequently fully recovered, supporting the heterologous prime-boost strategy against COVID-19.

21 November 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
Theresia SantiTheresia Santi
Theresia Santi
RRRidwansyah Ridwansyah
Ridwansyah Ridwansyah
VSVeli Sungono
Veli Sungono
NWNatalia Widjaya
Natalia Widjaya
KEKeinata Nabila Euqenekim
Keinata Nabila Euqenekim
JJJuandy Jo
Juandy Jo
Background/Objectives: In the absence of specific antiviral therapy for dengue viral infection, vaccination remains the most effective preventive measure. Two dengue vaccines have been licensed in Indonesia; however, concerns regarding vaccine hesitancy persist. This study aimed to assess dengue vaccine hesitancy among Indonesian office workers, comprising healthcare and non-healthcare workers. Methods: A cross-sectional study with an online survey was conducted between February 1 and April 30, 2025. Eligible participants were adults (≥18 years) employed in office-based settings, including healthcare facilities. Questionnaires were disseminated through company management teams and included 37 items on demographic characteristics, vaccination intentions, and underlying motivations. Data were analyzed to identify determinants of vaccine hesitancy. Results: A total of 377 respondents participated, the majority of whom were from West Java (335; 88.9%). One-third of respondents reported uncertainty regarding dengue vaccination (33.4% “not sure”), which was paralleled by hesitancy to pay for vaccination (43.2% “not sure”). Multivariable logistic regression analysis identified five significant determinants of vaccine hesitancy, with willingness-to-pay emerging as the strongest factor (β coefficient = 2.024; OR = 7.57; 95% CI = 4.06–14.10; p-value < 0.01). Conclusions: Approximately one-third of the surveyed Indonesian office workers exhibited hesitancy toward dengue vaccination. Willingness-to-pay was the most influential determinant of vaccine acceptance. Targeted strategies to address financial concerns and improve confidence in dengue vaccination are essential for strengthening workforce protection and national preparedness against dengue outbreaks.

1 October 2021
Verified
Journal Article
Closed access
Theresia SantiTheresia Santi
Theresia Santi
BSBaringin De Samakto
Baringin De Samakto
LKLina Kamarga
Lina Kamarga
FHFeronica Kusuma Hidayat
Feronica Kusuma Hidayat
FHFerry Hidayat
Ferry Hidayat

29 October 2024 in Paediatrica Indonesiana
Verified
Journal Article
Open access
PDF file
Theresia SantiTheresia Santi
Theresia Santi
APAri Prayitno
Ari Prayitno
ZMZakiudin Munasir
Zakiudin Munasir
SHSri Rezeki S. Hadinegoro
Sri Rezeki S. Hadinegoro
AHAlida Roswita Harahap
Alida Roswita Harahap
BHBadriul Hegar
Badriul Hegar
Background Diphtheria can be effectively prevented by adequate immunization. A combined vaccine against diphtheria toxoid, pertussis, and tetanus toxoid (DPT) is currently used in routine pediatric immunizations. Outbreaks of diphtheria could emerge in Indonesia as a consequence of declining routine vaccination during the COVID-19 pandemic. Objective To analyze the impact of the first (administered at 18-24 months of age ) and second diphtheria boosters (administered at 5-7 years of age ) in retaining protective levels of anti-diphtheria toxoid antibodies. We also investigated for relevant factors associated with anti-diphtheria toxoid antibody titers. Methods This cross-sectional study was conducted in the Senen District of Jakarta, Indonesia. The inclusion criteria were healthy children aged 6 to 7 years with documented history of DPT vaccination. Primary vaccination defined as 3 doses of DPT at age less than 1 year , first booster was DPT vaccination at 18-24 years of age, and second booster was diphtheria-tetanus (DT) vaccination received at 5 to 7 years of age. Peripheral blood specimens were obtained from participating children, after informed consent was provided by their parents. Antibodies against diphtheria in sera specimens were assessed by commercial anti-diphtheria toxoid immunoglobulin G (IgG) enzyme-linked immunosorbent assay. Results There were 154 children included in the study, with a female majority (61%). Overall, specific humoral immunity against diphtheria was observed in 113 children (73.4%). There was no statistical difference in immunity level between genders. Importantly, children who received the first and second diphtheria booster had significantly higher anti-diphtheria antibody level than those who did not receive both diphtheria booster (P<0.001). Conclusion Booster vaccinations are crucial among school-age children in Indonesia to improve their anti-diphtheria immunity and to minimize a risk of diphtheria outbreaks.